Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy? [electronic resource]
Producer: 20090109Description: 489-92 p. digitalISSN:- 0302-2838
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Monoclonal, Humanized
- Bevacizumab
- Carcinoma, Renal Cell -- pathology
- Clinical Trials as Topic
- Combined Modality Therapy
- Humans
- Indoles -- therapeutic use
- Interferon-alpha -- therapeutic use
- Kidney Neoplasms -- pathology
- Nephrectomy -- methods
- Protein Kinases -- therapeutic use
- Pyrazoles -- therapeutic use
- Pyrimidines -- therapeutic use
- Pyrroles -- therapeutic use
- Sunitinib
- Survival Analysis
- TOR Serine-Threonine Kinases
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
No physical items for this record
Publication Type: Editorial
There are no comments on this title.
Log in to your account to post a comment.